Myriad Builds Case For Personalized Rheumatoid Arthritis Drugs
This article was originally published in The Gray Sheet
Executive Summary
Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.
You may also be interested in...
Crescendo Touts Rheumatoid Arthritis Dx Data Haul At ACR2016
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, is talking-up the results of four different clinical trials of its Vectra DA multi-analyte blood test for rheumatoid arthritis that were presented at this year's American College of Rheumatology meeting in Washington, DC.
Making The Most Of A Maturing Myriad Genetics
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.